tradingkey.logo

Ionis Pharmaceuticals Inc

IONS

43.000USD

-0.590-1.35%
收盤 07/03, 13:00美東報價延遲15分鐘
6.84B總市值
虧損本益比TTM

Ionis Pharmaceuticals Inc

43.000

-0.590-1.35%
關於 Ionis Pharmaceuticals Inc 公司
Ionis Pharmaceuticals, Inc. 從事核糖核酸 (RNA) 靶向治療。該公司有五種已上市藥物和一條產品線,涉及神經病學、心臟病學和其他患者需求高的領域。該公司有九種藥物處於 III 期開發階段,還有多種其他藥物處於早期和中期開發階段。該公司的產品包括 SPINRAZA、QALSODY、WAINUA、TEGSEDI 和 WAYLIVRA。SPINRAZA 用於治療脊髓性肌萎縮症 (SMA) 患者,這是一種進行性、使人衰弱且通常致命的遺傳疾病。QALSODY 是一種反義藥物,用於治療超氧化物歧化酶 1 肌萎縮側索硬化症 (SOD1-ALS) 的成年患者,這是一種罕見的神經退行性疾病,會導致運動神經元逐漸喪失並導致死亡。 WAINUA 是一種自行注射的皮下配體結合反義 (LICA) 藥物,用於治療患有遺傳性轉甲狀腺素介導的澱粉樣變性多發性神經病 (ATTRv-PN) 的成年人。
公司簡介
公司代碼IONS
公司名稱Ionis Pharmaceuticals Inc
上市日期May 17, 1991
成立日期1991
CEODr. Brett P. Monia, Ph.D.
員工數量1069
證券類型Ordinary Share
年結日May 17
公司地址2855 Gazelle Court
城市CARLSBAD
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編92010
電話17609319200
網址https://www.ionis.com/
公司代碼IONS
上市日期May 17, 1991
成立日期1991
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
180.98K
-0.30%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
152.00K
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
-0.03%
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
99.49K
-0.03%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
57.02K
+30.71%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
56.80K
--
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
56.66K
+2.15%
Dr. Eric E. Swayze, Ph.D.
Dr. Eric E. Swayze, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
48.55K
+0.86%
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
32.25K
--
Ms. Shannon L. Devers
Ms. Shannon L. Devers
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
15.94K
+101.50%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
180.98K
-0.30%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
152.00K
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
-0.03%
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
99.49K
-0.03%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
57.02K
+30.71%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
56.80K
--
收入明細
單位: USD更新時間: 3月4日 週二
單位: USD更新時間: 3月4日 週二
FY2020
FY2019
業務USD
名稱
營收
佔比
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
暫無數據
業務
地區
業務USD
名稱
營收
佔比
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
股東統計
更新時間: 7月3日 週四
更新時間: 7月3日 週四
持股股東
股東類型
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
14.84%
The Vanguard Group, Inc.
10.27%
T. Rowe Price Investment Management, Inc.
10.16%
Capital World Investors
7.77%
Capital Research Global Investors
6.60%
Other
50.36%
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
14.84%
The Vanguard Group, Inc.
10.27%
T. Rowe Price Investment Management, Inc.
10.16%
Capital World Investors
7.77%
Capital Research Global Investors
6.60%
Other
50.36%
股東類型
持股股東
佔比
Investment Advisor
67.26%
Investment Advisor/Hedge Fund
28.07%
Hedge Fund
13.12%
Research Firm
2.36%
Private Equity
1.60%
Sovereign Wealth Fund
1.08%
Pension Fund
0.93%
Individual Investor
0.81%
Bank and Trust
0.52%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
787
184.68M
116.03%
+8.73M
2025Q1
826
174.18M
109.45%
-1.97M
2024Q4
819
166.51M
104.84%
-2.69M
2024Q3
814
162.85M
103.55%
+6.60M
2024Q2
810
149.96M
102.64%
-3.87M
2024Q1
792
148.14M
101.63%
-5.27M
2023Q4
782
147.15M
102.53%
-3.26M
2023Q3
763
145.13M
101.24%
-1.40M
2023Q2
770
142.08M
99.29%
+364.04K
2023Q1
825
136.59M
95.51%
-5.80M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Fidelity Management & Research Company LLC
23.61M
14.84%
+924.09K
+4.07%
Mar 31, 2025
The Vanguard Group, Inc.
16.35M
10.27%
-88.61K
-0.54%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
16.18M
10.16%
+323.67K
+2.04%
Mar 31, 2025
Capital World Investors
12.36M
7.77%
+896.58K
+7.82%
Mar 31, 2025
Capital Research Global Investors
10.50M
6.6%
+10.50M
--
May 31, 2025
BlackRock Institutional Trust Company, N.A.
8.90M
5.59%
+21.73K
+0.24%
Mar 31, 2025
Wellington Management Company, LLP
8.42M
5.29%
-255.73K
-2.95%
Mar 31, 2025
Bellevue Asset Management AG
7.85M
4.93%
-15.50K
-0.20%
Mar 31, 2025
State Street Global Advisors (US)
4.85M
3.04%
-581.28K
-10.71%
Mar 31, 2025
Deep Track Capital LP
4.56M
2.87%
+2.63M
+136.01%
Mar 31, 2025
查看更多
持股ETF
更新時間: 7月2日 週三
更新時間: 7月2日 週三
機構名稱
佔比
ARK Genomic Revolution ETF
3.36%
Tema Neuroscience and Mental Health ETF
2.73%
Capital Group US Small and Mid Cap ETF
2.15%
Virtus LifeSci Biotech Products ETF
1.66%
SPDR S&P Biotech ETF
1.45%
Tema Cardiovascular and Metabolic ETF
1.25%
WisdomTree BioRevolution Fund
1.17%
Direxion Daily S&P Biotech Bull 3X Shares
0.86%
Franklin Genomic Advancements ETF
0.62%
Invesco NASDAQ Future Gen 200 ETF
0.61%
查看更多
ARK Genomic Revolution ETF
佔比3.36%
Tema Neuroscience and Mental Health ETF
佔比2.73%
Capital Group US Small and Mid Cap ETF
佔比2.15%
Virtus LifeSci Biotech Products ETF
佔比1.66%
SPDR S&P Biotech ETF
佔比1.45%
Tema Cardiovascular and Metabolic ETF
佔比1.25%
WisdomTree BioRevolution Fund
佔比1.17%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.86%
Franklin Genomic Advancements ETF
佔比0.62%
Invesco NASDAQ Future Gen 200 ETF
佔比0.61%
分紅派息
近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
tradingkey.logo
tradingkey.logo
日內數據由路孚特(Refinitiv)提供,並受使用條款約束。歷史及當前收盤數據均由路孚特提供。所有報價均以當地交易所時間為準。美股報價的即時最後成交數據僅反映透過納斯達克報告的交易。日內數據延遲至少15分鐘或遵循交易所要求。
* 參考、分析和交易策略由提供商Trading Central提供,觀點基於分析師的獨立評估和判斷,未考慮投資者的投資目標和財務狀況。
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有
KeyAI